CymaBay Therapeutics Inc. (CBAY)
(Delayed Data from NSDQ)
$13.12 USD
+0.67 (5.38%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.12 (%) 5:22 PM ET
NA Value NA Growth NA Momentum NA VGM
View All Zacks #1 Ranked Stocks
Brokerage Reports
0 items in cart
[CBAY]
Reports for Purchase
Showing records 1 - 20 ( 236 total )
Industry: Medical - Generic Drugs
4Q Recap; We Expect Acquisition By Gilead to Close in 1Q24 As Planned; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 25.00
Industry: Medical - Generic Drugs
Gilead to Acquire CymaBay; FDA Sets August 14 PDUFA Date
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 10.00
Industry: Medical - Generic Drugs
Post-Hoc Analysis of Phase 3 ENHANCE Shows IL-31 Reduction With Seladelpar Correlates With Reduced Pruritus; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Generic Drugs
We Believe the Change in Commercial Leadership Strengthens the Company Ahead of a Potential 3Q24 Launch; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Generic Drugs
Seladelpar NDA For PBC Submitted Ahead of Our Previous Expectation of Early 2024; Raising PT to $28; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Generic Drugs
Optimized Entry and Exit Levels for CBAY 112123
Provider: Stock Traders Daily
Analyst: Research Department
Price: 12.50
Industry: Medical - Generic Drugs
3Q Recap; U.S. Seladelpar Commercial Preparations Are Full Speed Ahead; Increasing PT to $24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Generic Drugs
Top-line Results of RESPONSE Positive All-Around; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Generic Drugs
2Q Recap: Pivotal RESPONSE Readout Next Month, While IDEAL Is Poised to Reset the Bar; Raise PT to $21
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Generic Drugs
New IDEAL Study Evaluates Seladelpar''s Potential in PBC Patients Outside of Current PBC Clinical Guidelines; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Generic Drugs
On the Cusp of Pivotal RESPONSE Data, We Expect Seladelpar to Be the Leading 2L Treatment for PBC; Raise PT to $19
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 25.00
Industry: Medical - Generic Drugs
ILC 2023 Presentations Elucidate Seladelpar''s Mechanism in PBC; Approaching RESPONSE Readout in 3Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Generic Drugs
1Q Recap; Phase 3 RESPONSE Top-line Readout On Target in 3Q23; We Expect a Compelling Dataset; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Generic Drugs
We Remain Highly Confident in RESPONSE; Pruritus Reduction and ALP Normalization to Drive Rapid Uptake; PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Generic Drugs
3Q Recap; AASLD Poster Highlights Seladelpar''s Lipids Improvement; RESPONSE Top-line On Target in 3Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Generic Drugs
2Q Recap; Pivotal Phase 3 RESPONSE Top-Line Data Due in 3Q23; Virtual Investor Day Planned Next Month; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Generic Drugs
RESPONSE Fully Enrolled; Timing of Top-Line Readout Confirmed Next Year; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Generic Drugs
DDW Presentations Highlight Seladelpar''s Long Term Clinical Benefits in Diverse PBC Patient Populations; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 5.00
Industry: Medical - Generic Drugs
1Q22 Recap: RESPONSE to Reach Full Enrollment Next Quarter; Phase 2a Data on MBX2982 Around YE22; Calibrate PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50
Industry: Medical - Generic Drugs
Publication in Highly Regarded Journal of Hepatology Highlights Robust Seladelpar Phase 2 PBC Data
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Price: 12.50